Improving micrograft patency.
To help clarify many of the controversial issues affecting early microvascular graft patency, a series of experiments was performed comparing the relative importance of graft material used alone and in conjunction with antiplatelet agents. Using a rat carotid model employing 1 cm micrografts with 1 mm luminal diameter, this study demonstrated that 1) untreated 1 mm polytetrafluoroethylene (PTFE) and human umbilical vein (HUV) micrografts have unacceptably low patency rates; 2) treatment with the antiplatelet agents indomethacin, ibuprofen, and aspirin significantly improved micrograft patency; 3) differences in patency among the three agents were not significant; and 4) PTFE had higher patency rates than HUV, although this difference did not achieve significance.
Nichter
L S
LS
Division of Plastic and Reconstructive Surgery, University of Southern California School of Medicine, Childrens Hospital of Los Angeles.
Bindiger
A
A
D000818:Animals; D001241:Aspirin / Q000494:pharmacology; D001807:Blood Vessel Prosthesis; D002343:Carotid Artery, Internal / Q000601:surgery; D005260:Female; D006801:Humans; D007052:Ibuprofen / Q000494:pharmacology; D007213:Indomethacin / Q000494:pharmacology; D007601:Jugular Veins / Q000637:transplantation; D008866:Microsurgery / Q000379:methods*; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D011138:Polytetrafluoroethylene; D051381:Rats; D011919:Rats, Inbred Strains; D014471:Umbilical Veins / Q000637:transplantation*; D014654:Vascular Patency / Q000187:drug effects*
D010975:Platelet Aggregation Inhibitors; D011138:Polytetrafluoroethylene; D001241:Aspirin; D007052:Ibuprofen; D007213:Indomethacin